• Th Jouary.
• Service d'oncologie médicale, hôpital François-Mitterrand, 4, boulevard Hauterive, 64000 Pau, France; Service de dermatologie, hôpital Saint-André, 1, rue Jean-Burguet, 33075 Bordeaux, France. Electronic address: thomas.jouary@ch-pau.fr.
• Ann Dermatol Vener. 2014 Dec 1;141 Suppl 4:S630-42.

AbstractThe present "what's new in oncology in 2014?" is in keeping with data reported in the past years. Indeed, metastatic melanoma still keeps the lion's share. The results of the combinations schedules with BRAF and MEK inhibitors showed an improvement in progression-free survival. Otherwise, resistance mechanisms to MAPKinase pathway inhibitors are of interest worldwide. Nevertheless, more fundamental and transversal researches are currently being investigated than validated schedules in daily clinical practice. Following anti-CTLA-4 drugs, second-generation immunotherapies, including anti-PD1 and PD-L1 molecules, confirmed their results in extended cohorts. In the setting of localized melanoma, the final results from MLST-1, Morton's study, regarding the sentinel node procedure versus observation alone, prompted a new enhancement in the sentinel node controversy. From another point of view, "what is not new in oncology in 2014?" In this area, the absence of original investigations on the primary melanoma detection in France and the absence of innovations in the adjuvant treatment of melanoma after surgery should be mentioned. While recent revolutionary drugs, i.e. targeted therapies and immunotherapies, will know advances under the resistance pressure in a near future, a revolution is still awaited in melanoma earlier stages.Copyright © 2014 Elsevier Masson SAS. All rights reserved.

40 keywords...

hide…